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Abstract
The objective of this study is to prepare a non-viral carrier of gene transfection from various polysaccha-
rides and evaluate the feasibility in gene expression for mesenchymal stem cells (MSCs). Various amounts
of spermine were chemically introduced into pullulan, dextran and mannan with a molecular weight of
around 40 000 or pullulan with different molecular weights to prepare cationized polysaccharides with
different extents of spermine introduced (spermine–polysaccharide). Each cationized polysaccharide was
complexed with a plasmid DNA at various ratios and in vitro gene transfection was investigated for rat bone
marrow-derived MSCs. The level of gene expression depended on the type of cationized polysaccharide.
The highest level was observed for the complex of spermine–pullulan and plasmid DNA. Additionally,
the level also depended on the molecular weight of pullulan and the extent of spermine introduced to
pullulan. Suppression of gene expression with chlorpromazine and methyl-β-cyclodextrin of endocytosis
inhibitors demonstrated that the cellular uptake of spermine–pullulan–plasmid DNA complexes was medi-
ated by clathrin- and raft/caveolae-dependent endocytic pathways. The cationized pullulan is a promising
non-viral carrier of plasmid DNA for MSCs.
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1. Introduction
The recent advent of genome sciences has elucidated genetic sequences which are
related to the occurrence of diseases and the proliferation and differentiation of cells
for tissue repair. On the other hand, with rapid development of cell biology and tis-
sue regeneration medicine, it has been possible to make use of various precursor and
stem cells with high potentials of proliferation and differentiation for cell therapy.
One of the most promising cells are bone-marrow-derived mesenchymal stem cells
(MSCs), which are multipotent adult stem cells readily isolatable from the bone
marrow of patients themselves [1, 2]. It is well recognized that MSCs can differen-
tiate into not only osteoblasts, chondrocytes, neurons and skeletal muscle cells, but
also vascular endothelial cells [3] and cardiomyocytes [4, 5]. However, since often
the cells are not powerful therapeutically, it is of prime importance for success-
ful cell therapy to develop a method of genetic cell engineering aiming at efficient
activation and manipulation of cellular functions. To achieve this genetic engineer-
ing of cells, virus carriers have been mainly used because of the high efficiency of
gene transfection [6–12]. However, there are several problems to be resolved for the
clinical applications, such as the antigenicity and toxicity of virus itself or the pos-
sibility of disease transfection. Therefore, efficient technology and methodology of
gene transfection without virus vectors are highly desirable.
Many types of cationized polymers [13] and cationized liposomes [14–16] have
been designed, while complexation with them enabled plasmid DNA to neutral-
ize the anionic charge, as well as to reduce the molecular size, which is preferable
to enhance the efficiency of plasmid DNA transfection. Although the expression
level of plasmid DNA was enhanced by complexation with the cationized car-
riers, the electrostatic interaction of the positively charged complexes with the
cell surface of negative charge is not cell-specific. Therefore, it is necessary to
technologically improve the selectivity of complexes for target cells. Several ap-
proaches for the cell-specific gene delivery have been investigated by making use of
cell-surface receptors [17] (peptide-recognition receptor [8, 18–20] or sugar chain-
recognition receptor [21–25]). Generally, the ligand for the receptor is covalently
linked to cationized polymers. For example, the liver targeting of a plasmid DNA
is achieved through the covalent conjugation of high-molecular-weight polylysine
with asialoorosomucoid [26, 27]. Coupling of galactose residues enabled poly-
ethylenimine to selectively deliver genes to hepatocytes via the asialoglycoprotein
receptor-mediated pathway [28, 29].
Gene-delivery systems have been investigated by making use of cationized
polysaccharides, such as cationized dextran [30–32], schizophyllan [33] and chi-
tosan [34]. Advantages of the polysaccharide-based carrier over other cationized
polymers are the presence of hydroxyl groups available for simple chemical mod-
ification and the cell internalization possibly accelerated by a sugar-recognition
receptor of cell surface.
It is well recognized that the level of gene expression is greatly influenced by
the physicochemical properties of cationized polymer carriers for complexation
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including the molecular weight, the percentage of cationized residues introduced
to the carrier polymer and the type or the percentage of amine compounds intro-
duced for cationization. To our best knowledge, there is no report where the effect
of polysaccharide type on the level of gene expression was systematically investi-
gated. In this study, various polysaccharides, pullulan, dextran and mannan, with a
similar molecular weight of around 40 × 103, or pullulan with different molecular
weights were cationized by the chemical introduction of spermine to obtain various
cationized polysaccharide derivatives with different extents of spermine introduced.
A plasmid DNA was complexed with the cationized polysaccharide derivatives in
aqueous solution, and the apparent molecular size and zeta potential of the com-
plexes were measured. The effect of the polysaccharide type, the molecular weight
and the extent of spermine introduced on the level of gene expression for MSCs, was
investigated. Furthermore, we examined the cellular uptake of spermine–pullulan–
plasmid DNA complexes using endocytosis inhibitors.
2. Materials and Methods
2.1. Materials
Pullulan with different weight-average molecular weights (5.9 × 103, 11.8 × 103,
22.8×103, 47.3×103, 112×103 and 212×103) was purchased from Hayashibara
Biochemical Laboratories (Okayama, Japan). Dextran and mannan were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA) and Nacalai Tesque (Kyoto,
Japan), respectively. When determined by high-performance liquid chromatography
(LC-8020 model-II, Tosoh, Tokyo, Japan) using the pullulan with different weight-
average molecular weights as standards, the weight-average molecular weights of
dextran and mannnan were 57 × 103 and 36 × 103, respectively. Spermine was pur-
chased from Sigma. Other chemicals were obtained from Nacalai Tesque and used
without further purification.
2.2. Preparation of Cationized Polysaccharide Derivatives
Spermine was chemically introduced to the hydroxyl groups of polysaccharide
by a N,N′-carbonyldiimidazole (CDI) activation method [35]. Briefly, 9.28 mmol
spermine and various molar amounts of CDI were added to 50 ml of dehydrated
dimethyl sulfoxide containing 50 mg of each polysaccharide (Table 1). The molar
ratio of CDI initially added to the hydroxyl groups (OH) of polysaccharide was
defined as the [CDI]/[OH] ratio.
Following agitation at 35◦C for 20 h, the reaction mixture was dialyzed against
double-distilled water (DDW) for 2 days. The cut-off molecular weights of dialysis
membrane used are 3500 (Spectrum Laboratories, Rancho Domiguez, CA, USA)
and (12–16) × 103 (Viskase, Willowbrook, IL, USA) for pullulan with molecular
weights of 5900 and 11.8 × 103, and other polysaccharides, respectively. Then,
the dialyzed solution was freezed-dried to obtain samples of spermine-introduced
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Table 1.








22.8 2.69 5.60 11.0 23.0 32.5
47.3 1.07 5.95 12.3 20.4 32.9






a Molar ratio of N,N′-carbonyldiimidazole (CDI) initially added to the
hydroxyl groups (OH) of polysaccharide.
b Molar percentage of spermine introduced to the hydroxyl groups of
polysaccharide.
polysaccharide (spermine–polysaccharide). The spermine introduction was deter-
mined from the conventional element analysis and expressed by the molar extent of
spermine introduced to the hydroxyl groups of each polysaccharide.
2.3. Preparation of Plasmid DNA
The plasmid DNAs used were the pGL3 plasmid coding a firefly luciferase
gene (Luciferase Reporter Vectors-pGL3, Promega, Madison, WI, USA) and the
pEGFP-N1 plasmid coding enhanced green fluorescent protein (Takara Bio, Shiga,
Japan). The plasmid DNA was propagated in Escherichia coli (strain DH5α) and
purified with the Qiagen plasmid Mega kit (Qiagen K. K., Tokyo, Japan) according
to the manufacturers’ instructions. Both the yield and purity of plasmid DNA were
evaluated by UV spectroscopy (Ultrospec 2000, Pharmacia Biotech, Cambridge,
UK). The absorbance ratio at wavelengths of 260 to 280 nm for plasmid DNA so-
lution was measured to be between 1.8 and 2.0.
2.4. Preparation of Spermine–Polysaccharide–Plasmid DNA Complexes
Polyion complexes (PIC) were prepared by mixing an aqueous solution of
spermine–polysaccharide with that of plasmid DNA. Briefly, varied amounts of
spermine–polysaccharide were dissolved in 50 µl DDW and mixed with 50 µl
10 mM phosphate-buffered saline solution (PBS, pH 7.4) containing 100 µg plas-
mid DNA, followed by leaving for 15 min at room temperature to obtain various
PIC of spermine–polysaccharide and plasmid DNA. The PIC composition was cal-
culated on the basis of the nitrogen number of spermine–polysaccharide (N) per
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phosphorus number of plasmid DNA (P) and expressed as the N/P ratio. To com-
plex the plasmid DNA with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA),
50 µl Opti-MEM (Invitrogen) containing 5.0 µg Lipofectamine was mixed with
50 µl Opti-MEM containing 2.5 µg plasmid DNA, followed by leaving for 15 min
at room temperature.
2.5. Electrophoretic Measurement of Spermine–Polysaccharide–Plasmid DNA
Complexes
PIC were prepared in 10 mM PBS solution at a N/P ratio of 3.0. After 15 min
incubation, 10 µl of the complex was added to 3 µl of a loading buffer (0.1%
sodium dodecyl sulfate, 5% glycerol and 0.005% bromophenol blue) and applied
to an 1 wt% agarose gel in Tris-borate-ethylenediaminetetraacetic acid buffer solu-
tion (TBE, pH 8.3) containing 0.1 mg/ml ethidium bromide (EtBr). Electrophoretic
evaluation of the PIC was carried out in TBE solution at 100 V for 30 min. The
gel was imaged with a UV transilluminator (Gel Doc 2000, Bio-Rad Laboratories,
Segrate, Italy).
2.6. Dynamic Light Scattering (DLS) and Electrophoretic Light Scattering (ELS)
Measurements
PIC were prepared in 10 mM PBS solution at a N/P ratio of 3.0. The DLS mea-
surement was carried out using a DLS-DPA-60HD instrument (Otsuka Electronic,
Osaka, Japan) equipped with an Ar+ laser at a detection angle of 90◦ at 25◦C for
15 min. In the present study, the autocorrelation function of samples was analyzed
based on the cumulant method and the Rs value was calculated automatically by
the equipped computer software and expressed as the apparent molecular size of
samples. On the other hand, the zeta potential was measured using ELS-7000AS
instrument (Otsuka Electronic) at 25◦C and an electric field strength of 100 V/cm.
From the determined electrophoretic mobility, the zeta potential was automatically
calculated using the Smoluchowski equation. Light scattering measurement was
done three times for every sample.
2.7. Lectin-Induced Aggregation of Spermine–Polysaccharide–Plasmid DNA
Complexes
PIC were prepared in PBS at a N/P of 3.0, followed by incubation at room tem-
perature for 15 min. To 100 µl of the PIC solution, 100 µl of Ricinus communis
agglutinin of lectin recognizable to galactose (RCA120, Seikagaku, Tokyo, Japan,
500 µg/ml) was added, followed by incubation at room temperature. The time pro-
file of solution turbidity change was measured at a wavelength of 500 nm. To
confirm the specificity of lectin–sugar interaction, D-galactose was added 40 min
after RCA120 addition. The results were expressed as the percentage of the solu-
tion absorbance to that of spermine–polysaccharide–plasmid DNA complex alone.
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2.8. In Vitro Gene Transfection Experiment
MSC culture was performed according to the method previously described [1].
Briefly, 3-week-old male Wistar rats (Shimizu Laboratory Supplies, Kyoto, Japan)
were killed to isolate the femur and tibia, and the bone marrow was harvested by
flushing the bone with PBS. The suspension of bone marrow cells in PBS was
placed into 25 cm2 cell-culture flasks (Corning, Corning, NY, USA) and cultured
in α-minimum essential medium (αMEM) supplemented with 15 vol% bovine fe-
tal calf serum (FCS, Hyclone Laboratories, Logan, UT, USA) and 1 wt% mixed
penicillin and streptomycin solution (Sigma-Aldrich, control medium). After in-
cubation at 37◦C in 5% CO2 and 95% air at atmospheric pressure for 3 days,
non-adherent cells were removed. Adherent cells were further cultured by exchang-
ing the fresh control medium every 3 days. The cells were collected with 0.25 wt%
trypsin-containing 0.8 mM ethylenediaminetetracetic acid solution in PBS, and then
subcultured in 225 cm2 cell-culture flasks to allow to grow at 80% cell confluency
for the following transfection experiments.
The transfection experiments were performed independently in triplicate. MSCs
were seeded on each well of 12 multi-well cluster plate (Corning) at a density of 5×
104 cells/well and cultivated in 1 ml of control medium for 24 h. Immediately after
the medium was exchanged by FCS-free control medium, PIC solution (100 µl) was
added, followed by 6 h incubation for cell gene transfection. Then, the medium was
changed to the control medium and cells were incubated for another 24 h.
Cells were washed with PBS once, lysed in 200 µl of a cell-culture lysis reagent
(Promega, Madison, WI, USA), transferred into a micro reaction tube, and the cell
debris was separated by centrifugation (14 × 103 rpm, 20 min). Then, 100 µl lu-
ciferase assay reagent (Promega) was added to 20 µl supernatant, while the relative
light unit (RLU) of the samples was determined by a luminometer (MicroLumat-
Plus LB 96V, Berthold, Tokyo, Japan). The total protein of each well was deter-
mined with a bicinchonic acid (BCA) Protein assay kit (Pierce, Rockford, IL, USA)
according to the manufacturers’ instructions in order to normalize the influence of
number variance of cells on the luciferase activity. Each experimental group was
carried out three times independently. Chlorpromazine (CPZ, clathrin-mediated en-
docytosis inhibitor [36, 37], 10 µg/ml, Sigma) and methyl-β-cyclodextrin (MβCD,
raft/caveolae-mediated endocytosis inhibitor [38–40], 10 mM, Sigma) were pre-
incubated for 30 min, and then the similar transfection experiment was performed to
evaluate the endocytosis pathway of spermine–pullulan–plasmid DNA complexes.
2.9. Evaluation of Plasmid DNA Internalization
Plasmid DNA was labeled with rhodamine using the Label IT® Fluorescein isoth-
iocyanate (FITC) Labeling Kit (Mirus®, Madison, WI, USA) according to the
manufacturers’ instructions. After transfection culture for 1 day with the free FITC-
labeled plasmid DNA or the complex with Lipofectamine 2000® or spermine–
polysaccharide, the cells were treated in cold acetate-buffered solution containing
0.3 vol% acetic acid, 0.085 M NaCl and 5.0 mM KCl for 1 min, then the cells were
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washed with cold PBS to remove the complexes bound onto the cell surface. The
cells of three wells were collected by the trypsinization, and the results were con-
sidered as an average value of triplicates, while ten thousand cells were measured
by the fluorescence activated cell sorter (FACSCalibur, Becton Dickinson, Franklin
Lakes, NJ, USA) with Cell Quest Pro Software. The percentage of FITC-positive
cells was calculated by setting the background population as 98% negative when
analyzing control cells [41].
2.10. Microscopic Observation of Intracellular Localization
Plasmid DNA was labeled with Cy5 using the Label IT® Cy5 Labeling Kit
(Mirus®). After the transfection culture for 1 day with the complex of Cy5-
labeled plasmid DNA and spermine–polysaccharide, cells were washed and fixed
with 0.25 wt% glutaraldehyde solution in PBS, followed by staining nucleus with
Hoechst 33342 (Molecular Probes, Eugene, OR, USA). Imaging data of cells
were collected on an Olympus Fluoview FV300 confocal laser scanning micro-
scope (Olympus, Tokyo, Japan) and processed with Adobe Photoshop 6.0 software
(Adobe Systems, San Jose, CA, USA).
2.11. Cell Viability
Cytotoxicity was assayed using a cell counting kit (Nacalai Tesque). Cells were
seeded on each well of 96 multi-well cluster plate (Corning) at a density of 1 ×
104 cells/well and cultivated in the control medium for 24 h. The medium was
changed to the fresh FCS-free control medium, and 10 µl of the PIC solution was
applied to each well, followed by 6 h incubation. Then, the medium was changed
to the control medium and 10 µl 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-
(2,4-disulfophenyl)-2H-tetrazolium (WST-8) solution was added and the cells were
incubated for another 3 h. The absorbance of samples was measured at 450 nm
by VERSAmax microplate reader (Molecular Devices, Sunnyvale, CA, USA). The
percent cell viability was expressed as 100% for control (non-treated cells).
2.12. Statistical Analysis
All the data were expressed as the mean ± the standard deviation of the mean. Sta-
tistical analysis was performed based on the ANOVA, followed by Fisher’s PLSD
and significance was accepted at P < 0.05.
3. Results
3.1. Cationization of Polysaccharide
Spermine was chemically introduced to the hydroxyl groups of polysaccharide by
the CDI activation method (Table 1). The extent of spermine introduced could be
changed by altering the amount of CDI added initially, and but no big difference
in the introduced extent was observed in terms of the type and molecular weight of
polysaccharide used.
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3.2. Characterization of Spermine–Polysaccharide–Plasmid DNA Complexes
To confirm the formation of polyion complexes and characterize their physico-
chemical properties, electrophoresis analysis, DLS and ELS measurement were
performed.
Figure 1 shows the electrophoretic patterns of polyion complexes of plasmid
DNA and spermine–polysaccharide prepared at a N/P ratio of 3.0. Migration of
plasmid DNA was retarded and became invisible by complexation with spemine-
polysaccharide.
Table 2 summarizes the physicochemical properties of polyion complexes pre-
pared at a N/P ratio of 3.0. The apparent molecular size and the zeta potential of
free plasmid DNA were around 400 nm and −15 mV, respectively. Irrespective of
Figure 1. Agarose gel electrophoresis of spermine–polysaccharide–plasmid DNA complexes prepared
at a N/P ratio of 3.0. Shown are DNA marker (a), free plasmid DNA (b) or the complexes of plasmid
DNA and spermine derivatives of pullulan (c), dextran (d) and mannan (e). The [CDI]/[OH] ratio of
spermine–polysacccharide used for cationization is 1.5.
Table 2.
Apparent molecular size and zeta potential of plasmid DNA complexed at a N/P ratio of 3.0 with
cationized polysaccharides
Apparent molecular size (nm) Zeta potential (mV)
Pullulan 226.3 ± 51.9 +12.2 ± 1.5
Dextran 157.0 ± 28.3 +14.0 ± 0.1
Mannan 293.5 ± 28.5 +12.0 ± 0.5
Free plasmid DNA 409.5 ± 61.2 −14.7 ± 9.5
Values are means ± SD.
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Figure 2. Time-course of the turbidity change of spermine–polysaccharide–plasmid DNA complexes
prepared at a N/P ratio of 3 after addition of RCA 120. Galactose was added 40 min after RCA
120 addition (indicated by an arrow). The type of polysaccharide used for spermine introduction is
pullulan (!), dextran (") and mannan (Q). The [CDI]/[OH] ratio of spermine–polysacccharide used
for cationization is 1.5.
the polysaccharide type, the apparent molecular size and zeta potential was around
160–280 nm and 10–16 mV, respectively.
In addition to the physicochemical properties of spemine–polysaccharide-
plasmid DNA complexes, their biological properties, such as sugar–lectin inter-
action, were investigated.
Figure 2 shows the time-course of solution absorbance change of spermine–
polysaccharide–plasmid DNA complexes after the addition of RCA120 lectin. The
solution absorbance increased time-dependently, although the increment pattern of
depended on the polysaccharide type. When galactose was added to the solution,
the absorbance decreased.
3.3. In Vitro Gene Transfection of Spermine–Polysaccharide–Plasmid DNA
Complexes
The in vitro gene transfection for MSCs was performed by the plasmid DNA com-
plexed with spermine derivatives of different polysaccharides to evaluate the effect
of polysaccharide type on the level of gene expression, the cellular internalization
efficiency and the intracellular trafficking.
Figure 3 shows the effect of the type of polysaccharides used for spermine in-
troduction on the luciferase expression of spermine–polysaccharide–plasmid DNA
complexes at a N/P ratio of 3.0 for MSCs. The level of gene expression by the
spermine–pullulan–plasmid DNA complexes was significantly higher than that of
free plasmid DNA and the plasmid DNA complexes of Lipofectamine 2000 or the
spermine derivatives of other polysaccharides.
Figure 4 shows the fluorescence histogram of MSCs 1 day after transfection
with free FITC-labeled plasmid DNA or the complex of Lipofectamine 2000® or
spermine derivatives of different polysaccharide types. The percentages of plasmid
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Figure 3. The effect of different polysaccharides for the introduction of luciferase plasmid DNA
complex in MSCs. The amount of plasmid DNA applied is 2.5 µg/well and the N/P ratio is 3.0.
∗P < 0.05 versus the expression level of complexes prepared by other spermine–polysaccharides.
†P < 0.05 versus the expression level of complexes prepared by Lipofectamine 2000®.
(a)
(b)
Figure 4. Fluorescence histogram of MSCs 1 day after non-transfection (a) or transfection with free
FITC-labeled plasmid DNA (b) or the complex of Lipofectamine 2000® (c) or spermine derivatives
of pullulan (d), dextran (e) and mannan (f). The amount of plasmid DNA applied is 2.5 µg/well and
the N/P ratio is 3.0.






DNA internalized were 3.0, 18.0, 71.8, 46.5 or 36.3 for MSCs transfected with
free plasmid DNA, the complex of Lipofectamine 2000® or spermine derivatives of
pullulan, dextran and mannan, respectively.
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(a) (b)
(c)
Figure 5. Confocal laser microscopic images of MSCs 1 day after transfection with GFP plasmid
DNA complex of spermine derivatives of pullulan (a), dextran (b) and mannan (c). The plasmid DNA
was labeled with Cy5. The amount of plasmid DNA used for transfection is 2.5 µg. The N/P ratio of
spermine–polysaccharide–plasmid DNA complex is 3.0. The red, green and blue points indicate the
plasmid DNA, GFP expressed and cell nucleus, respectively. This figure is published in the online
edition of this journal, that can be accessed via http://www.brill.nl/jbs
Figure 5 shows the confocal laser microscopic images of MSCs 1 day after trans-
fection with spermine–polysaccharide–plasmid DNA complexes. Most of plasmid
DNA were localized around or in the nucleus of MSCs. Strong GFP expression
was observed in the MSCs transfected with spermine–pullulan–plasmid DNA com-
plexes.
3.4. MSC Gene Expression with Different Spermine–Pullulan Derivatives
To optimize the physicochemical condition of spemine–pullulan derivatives for
MSC gene expression, the effect of the pullulan molecular weight and the extent
of spermine introduced on the luciferase expression of spermine–pullulan–plasmid
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(a)
(b)
Figure 6. Effect of the pullulan molecular weight (a) and the extents of spermine introduced
to pullulan at the corresponding molecular weight (b) on the luciferase expression of sper-
mine–pullulan–plasmid DNA complexes for MSCs. The amount of plasmid DNA applied is 2.5 µg
and the N/P ratio is 3.0. ∗P < 0.05 versus the expression level of complexes prepared by other sper-
mine–pullulans. †P < 0.05 versus the expression level of complexes prepared by other spermine
derivatives of pullulan at the corresponding molecular weight.
DNA complexes for MSCs was investigated. The highest level was observed for
the complex of spermine derivative of pullulan with the molecular weight of 47 300
(Fig. 6A). On the other hand, the level of gene expression depended on the type of
spermine–pullulan derivatives with different percentages of spermine introduced.
The extent of spermine introduced where the highest level was observed depended
on the molecular weight of the pullulan used for spermine introduction (Fig. 6B).
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Figure 7. Effect of endocytosis inhibitors on the level of luciferase expression of sper-
mine–pullulan–plasmid DNA complexes prepared at the N/P ratio of 3.0 for MSCs. Cells were
pretreated with chloropromazine (PC) or methyl-β-cyclodextrin (PM) (solid columns) or without
(open column, P) endocytosis inhibitors before gene transfection. The plasmid DNA amount is 2.5 µg.
The molecular weight of pullulan used for spermine introduction is 47.3 × 103. ∗P < 0.05 versus the
expression level of cells transfected with the addition of endocytosis inhibitors.
To clarify the cellular uptake mechanism of spermine–pullulan–plasmid DNA
complexes, an inhibition test was performed.
Figure 7 shows the effect of endocytosis inhibitors on the level of luciferase ex-
pression of spermine–pullulan–plasmid DNA complexes prepared at the N/P ratio
of 3.0 for MSCs. The gene expression level was decreased by pre-treatment with
both endocytosis inhibitors, CPZ and MβCD.
3.5. Cytotoxicity of Spermine–Pullulan–Plasmid DNA Complexes
Figure 8 shows the viability of cells 3 h after exposure of PIC prepared at a N/P
ratio of 3.0. The cell viability decreased with the increased amount of plasmid DNA
added. However, less cytotoxicity was observed for the complex at 0.25 µg/ml, the
concentration at which the cell transfection experiment was performed.
4. Discussion
It has been demonstrated that cells themselves have good therapeutic potentials in
terms of their inherent targetability to the injury site and biological properties of
specific tissue [42–44]. However, the therapeutic efficacy of cells transplanted is
not always as high as expected, which is one of the largest problems in cell therapy.
This is because the grafting rate of cells transplanted is low and consequently the
biological functions of cells become low in the body. To tackle the problems, it is
indispensable to develop materials, technologies and methodologies to provide the
cells a local environment where the survival and biological functions of cells trans-
planted can be maintained or enhanced. One of the most effective technologies is
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Figure 8. Effect of the plasmid DNA amount on the viability of MSCs transfected with sper-
mine–pullulan–plasmid DNA complexes prepared at a N/P ratio of 3.0. The molecular weight of
pullulan used for spermine introduction is 47.3 × 103. The viability of cells without transfection is in-
dicated as 100%. The dotted line indicates the amounts of plasmid DNA used for the gene transfection
test.
genetic engineering. Genetic engineering is effective in not only artificially mod-
ifying the biological functions of cells, such as proliferation, differentiation, and
therapeutic abilities applicable to cell therapy [10, 45–51], but also developing the
basic research of cell biology and medicine which is important to identify and in-
vestigate genes regulating the biological function of cells. It has been reported that
the biological functions of genetically engineered cells are therapeutically superior
to those of the original ones [10, 52, 53].
It is indispensable to develop technology and methodology of gene transfection
for genetic engineering of cells. Considering the clinical use, it is necessary to de-
velop a non-viral gene carrier. For efficient gene transfection, it is important to
design carriers that can electrostatically bind to a genetic material, molecularly con-
dense the material size to a diameter range of several hundred nanometers, which
will facilitate the cell internalization. In addition, it is also necessary to develop a
carrier for a cell-specific delivery system, which allows genes to deliver specifically
to the target cell and enhance the expression level.
Among the non-viral materials applicable to a gene transfection carrier [54–56],
polysaccharide has an advantage over other substances in terms of the ability to
be recognized by the respective cell receptors of sugar specificity. This biologi-
cal recognition not only permits the receptor-specific targeting of substances to
the cell, but also accelerates their cell uptake via receptor-mediated endocytosis.
Therefore, we investigated the effect of polysaccharide type on the level of gene
expression. In this study, spermine was introduced to polysaccharide because sper-
mine is one of the polyamines present in the body, and cationization with spermine
converted gelatin to a non-viral carrier of plasmid DNA with a transfection effi-
ciency higher than that with other amine compounds [57]. In the present study,
the complex of cationized polysaccharide and plasmid DNA was formed at a N/P
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ratio of 3.0 because it has been previously reported that efficient gene transfec-
tion and less cytotoxicity were observed for the complex prepared at the N/P
ratio [58].
Dependence of the polysaccharide type on the level of gene expression (Figs
3 and 5) can be explained as follows. The electrophoresis analysis (Fig. 1) and the
DLS and ELS measurements (Table 2) revealed that physicochemical properties of
plasmid DNA complexes were not changed by the polysaccharide type, although
they were changed compared with those of free plasmid DNA. In the electrophore-
sis analysis, the images of DNA complexed with spermine–polysaccharide became
invisible. This is due to the dissociation of EtBr-plasmid DNA complex by the com-
plexation with spermine–polysaccharide, the so-called EtBr exclusion. On the other
hand, the lectin affinity assay (Fig. 2) revealed that the plasmid DNA complexes
with spermine derivatives of pullulan and dextran were strongly recognized by the
sugar-recognizable lectin, RCA120, which has the same recognition site, ASGPR.
It is possible that the pullulan and dextran chains present on the complex surface
are specifically recognized by the lectin, resulting in the formation of complex–
lectin aggregates. We have previously found that the ASGPR was expressed in
MSC [53]. Several researchers have demonstrated that pullulan of a polysaccharide
accumulates in the liver via the ASGPR at significantly higher amounts than other
water-soluble polymers [59, 60]. Based on these findings, it is highly suggested
that the polysaccharide type affects the cellular internalization of plasmid DNA
via ASGPR. It is conceivable that these recognition differences among polysaccha-
ride types contribute the cellular internalization, resulting in enhancing the level of
gene expression. This is also supported by the cellular internalization analysis result
(Fig. 4).
The highest level of gene expression was observed for the plasmid DNA complex
with spermine derivatives of pullulan. Therefore, for the pullulan derivatives, we
examine the effect of the molecular weight and the extent of spermine introduced
on the level of gene expression to demonstrate the dependence (Fig. 6). A similar
tendency of the gene expression level for MSCs was observed for HepG2, a human
hepatoma cell line which has ASGPR on the surface [58, 61]. The dependence on
the level of gene expression can be explained in terms of the apparent molecular size
of complexes as well as the interaction with the receptors of cell surface. First, it
is reported that a certain range of apparent molecular size of polyion complexes
was effective in enhancing the in vitro gene expression [62, 63]. Complexation
with spermine–pullulan with the same spermine introduction and molecular weights
ranging from 22.8 × 103 to 212 × 103 reduced the molecular size of plasmid DNA,
whereas smaller spermine–pullulan did not [58]. On the other hand, complexa-
tion with high amounts of spermine-introduced pullulan prepared at [CDI]/[OH]
ratios of 1.5 to 5.0 reduced the molecular size of plasmid DNA, whereas a lower
amount of spermine-introduced pullulan did not, irrespective of the pullulan mole-
cular weight [61]. It is possible that the compacted complex of reduced size is more
readily internalized by cells, resulting in enhanced gene expression. In addition, it
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has been demonstrated from the lectin affinity for pullulan chains localizing on the
complexes surface were different among spemine–pullulans used and that the com-
plexes strongly interacted with the lectin showed a higher level of gene expression
[58, 61]. Taken together, it is likely that the optimal molecular size of complexes
and the inherent affinity for the ASGPR results in effective increase of the cellular
internalization, resulting in enhanced gene expression. The percentage of spermine
introduced where the highest expression level was observed was different among
the molecular weights of pullulan used for spermine introduction (Fig. 6B). The
percent spermine introduction for the highest expression level tended to decrease
with an increase in the molecular weight of pullulan. At the same N/P ratio, the
number of spermine–pullulan complexed with plasmid DNA decreases with an in-
crease in the molecular weight and percent spermine introduced of pullulan. There
was an optimal molar number of the spermine–pullulan–plasmid DNA complex
for enhanced gene expression at a N/P ratio (data not shown). This result experi-
mentally indicates that a well-balanced combination of the spermine introduction
percentage and molecular weight of pullulan is necessary to enhance the level of
gene expression. However, the reason of the optimal number for the maximum gene
expression is not clear at present.
In the present study, two types of endocytosis inhibitors were used to exam-
ine the endocytic pathway of spermine-introduced pullulan. The complexes were
internalized by MSCs via both the clathrin- or raft/caveolae-dependent pathways
(Fig. 7). A similar result was reported for another cell by Kanatani et al. [64].
The endocytic pathway of the spemine-introduced pullulan will be independent
of the cell type. Lectin-mediated endocytosis has typically been characterized as
occurring either via the clathrin- or raft/caveolae-dependent pathways, although it
depends on the specific lectin involved [65]. The clathrin-mediated endocytosis of
spermine-introduced pullulan could be initiated by the non-specific adsorption of
cationic spermine groups to anionic proteoglycans of cell membrane, such as he-
paran sulfate. It has been reported that particles with a diameter less than 200 nm
non-specifically adsorbed on the cell were internalized via the clathrin-mediated
endocytosis and finally delivered to the lysosome, whereas particles of 500 nm in
diameter entered cells via the caveolae pathway and were never observed in the
lysosomal compartments [66]. Considering that the average diameter of spermine–
pullulan–plasmid DNA complexes was around 200 nm, they would be more sus-
ceptible to the clathrin-dependent endocytosis. It is known that the formation of
clathrin-coated vesicles occurs as the result of non-specific adsorption. The forma-
tion of calveola results from lectin-mediated endocytosis. Taken together, it is likely
that the complex is internalized by both the pathways.
Similar to other cationized carriers, cell toxicity increased with an increase of
complex added. However, high gene expression was observed by the spermine–
pullulan–plasmid DNA complex at the concentration of cell transfection (Fig. 8).
This lower toxicity clearly indicates that the spermine–pullulan is a feasible gene
carrier to enhance the gene expression for stem cells.
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